NEWS
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
Cyclacel Pharmaceuticals announced preclinical data for fadraciclib, a CDK2/9 inhibitor, demonstrating efficacy in metastatic colorectal cancer (CRC) models. Presented at the 2024 ASCO Annual Meeting, the study showed that fadraciclib significantly inhibited tumor growth, induced apoptosis, and triggered anaphase catastrophe in CRC patient-derived organoids (PDOs) and xenografts (PDXs). The research highlighted fadraciclib's superiority over standard chemotherapy and palbociclib in CRC models. Cyclacel's CEO, Spiro Rombotis, emphasized fadraciclib’s broad potential in multiple tumor types. Initial proof of concept data is expected in the second half of 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment